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A B S T R A C T
F⁠2-isoprostanes (F⁠2-IsoPs) have been considered markers of oxidative stress in various pulmonary diseases, but
little is known about their possible role in pulmonary fibrosis. In this study, we have investigated the potential
key role of F⁠2-IsoPs as markers and mediators of bleomycin (BLM)-induced pulmonary fibrosis in rats. During the
in vivo study, plasma F⁠2-IsoPs showed a peak at 7 days and remained elevated for the entire experimental period.
Lung F⁠2-IsoP content nearly tripled 7 days following the intratracheal instillation of BLM, and by 28 days, the
value increased about fivefold compared to the controls. Collagen deposition correlated with F⁠2-IsoP content in
the lung. Furthermore, from day 21 onwards, lung sections from BLM-treated animals showed α-smooth muscle
actin (α-SMA) positive cells, which were mostly evident at 28 days. In vitro studies performed in rat lung fibrob-
lasts (RLF) demonstrated that either BLM or F⁠2-IsoPs stimulated both cell proliferation and collagen synthesis.
Moreover, RLF treated with F⁠2-IsoPs showed a significant increase of α-SMA expression compared to control, in-
dicating that F⁠2-IsoPs can readily activate fibroblasts to myofibroblasts. Our data demonstrated that F⁠2-IsoPs can
be mediators of key events for the onset and development of lung fibrosis, such as cell proliferation, collagen
synthesis and fibroblast activation. Immunocytochemistry analysis, inhibition and binding studies demonstrated
the presence of the thromboxane A⁠2 receptor (TP receptor) on lung fibroblasts and suggested that the observed
effects may be elicited through the binding to this receptor. Our data added a new perspective on the role of
F⁠2-IsoPs in lung fibrosis by providing evidence of a profibrotic role for these mediators in the pathogenesis of
pulmonary fibrosis.
1. Introduction
Pulmonary fibrosis is a progressive and often lethal lung disease
characterized by excessive fibroblast activation and proliferation, re-
sulting in abnormal accumulation of extracellular matrix. Persistent in-
flammation and oxidative stress (OS) contribute to exacerbations and
disease progression [1,2]. Serum levels of OS markers are significantly
higher in patients with idiopathic pulmonary fibrosis (IPF) suggesting
that OS is involved in its pathogenesis [3,4]. Despite advances in re-
search and diagnostic approach, the molecular mechanisms of the dis-
ease are poorly understood and no effective therapies are currently
available. Further investigation of the factors involved in the initiation
and progression of pulmonary fibrosis is urgently needed to develop ef-
fective treatments against this disease.
Bleomycin (BLM) is one of the most widely used drugs for induc-
ing lung fibrosis in animals, due to its ability to reproduce a his-
tologic lung pattern similar to that described in patients undergoing
chemotherapy [5]. The BLM-induced pulmonary fibrosis was first de-
scribed as a side-effect of the BLM antineoplastic activity. This com-
plex of glycopeptide antibiotics from Streptomyces verticillus has long
been used as an antineoplastic drug for different malignancies [6–11].
Since BLM chelates metal ions producing a pseudoenzyme that reacts
with oxygen, it is believed that BLM antineoplastic activity is me-
diated by production of reactive oxygen species (ROS). This in turn
leads to single- or double-stranded DNA breaks [12–14] Genetic sus-
ceptibility [15] and the intra
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cellular hydrolase activity [16,17] appear to be involved in BLM toxic-
ity in lung. Moreover, pro-inflammatory cytokines play a relevant role
in BLM-induced lung injury [18]. The fibrogenic effect of BLM is con-
sidered secondary to OS. The early stage is characterized by the inflam-
matory response, followed by a chronic stage that leads to extracellular
matrix remodeling and collagen deposition [19].
The F⁠2-isoprostanes (F⁠2-IsoPs) are the most proximal products of
lipid peroxidation from arachidonic acid and are one of the most re-
liable approaches to evaluate OS in vivo in different pathologies [20].
They are considered OS markers of a wide variety of inflammatory lung
conditions [21–23]. Elevated levels of F⁠2-IsoPs have been reported in
exhaled breath condensates (EBC), plasma and urine from patients with
asthma [21,24], chronic obstructive pulmonary disease [25,26], cystic
fibrosis [27] and in the bronchoalveolar lavage (BAL) fluid from pa-
tients with different interstitial lung diseases [28,29].
In addition to being OS markers, F⁠2-IsoPs also elicit a wide vari-
ety of responses in different cell types [20], including lung cells. In the
lung, F⁠2-IsoPs regulate different cellular processes such as contraction
of airway smooth muscle [30,31], anion conductance across epithelial
cells [32], and stimulate adhesion and function of inflammatory cells
[33,34].
We previously demonstrated, in an experimental model of hepatic
fibrosis, that F⁠2-IsoPs are both markers of OS and mediators of fibrotic
effects. The addition of F⁠2-IsoPs to cultured hepatic stellate cells (HSC)
greatly stimulated cell proliferation and collagen synthesis, two hall-
marks of fibrosis [35]. In the liver, these fibrogenic events appear to be
mainly mediated through the activation of thromboxane A2 (TxA⁠2r or
TP receptor) receptors analogous [36,37].
Increasing evidence suggests that fibroblast activation and prolifer-
ation may be a critical event in the pathogenesis of pulmonary fibro-
sis [38,39]. Patients with active fibrosis usually present a greater pro-
fusion of fibroblastic foci. This is attributed to an increased number of
activated fibroblasts, many of which exhibit the characteristics of myofi-
broblasts [40,41]. These cells show intermediate features between the
smooth muscle cell and the fibroblast, and are characterized by the ex-
pression of α-smooth muscle actin (α-SMA) [42,43]. The localization of
myofibroblasts at sites undergoing active extracellular matrix deposition
suggests their important role in the progression of fibrotic lesion.
To date, only few studies have examined the effect of OS on the
release of F⁠2-IsoPs by lung fibroblasts [44–46]. However, no studies
performed have investigated the biological effects of F⁠2-IsoPs on lung
fibroblasts, with the exception of our previous in vitro work on hu-
man lung fibroblasts [46]. The present study was carried out in a rat
model of BLM-induced pulmonary fibrosis to better understand the role
of F⁠2-IsoPs in the onset/development of this disease. In particular, we
sought to investigate whether F⁠2-IsoPs produced after BLM injury elicit
a biological effect on lung fibroblasts, acting as mediators of the fibrotic
process.
2. Materials and methods
2.1. Animals
Male Sprague Dawley rats weighing 200–250 g (Harlan-Nossan, Cor-
rezzana, Italy) were maintained in a temperature- and light-controlled
environment, and fed Harlan Global diet and water ad libitum. All ani-
mal studies were approved by the Siena University Ethic-Deontological
Committee.
2.2. In vivo study
2.2.1. Animal model of bleomycin-induced pulmonary fibrosis
Forty-eight rats were randomly divided into 4 groups (n = 12 each).
Each treatment group included 6 control animals and 6 ani
mals treated with BLM. Anaesthetized rats received a single intratra-
cheal instillation of BLM (Nippon Kayaku, Sanofi Aventis, Milan, Italy),
5 mg/kg body weight in 0.3 ml phosphate buffered saline, as previously
described [47]. Control animals received the same volume of sterile
saline only. Animals were sacrificed at different time points (7, 14, 21
and 28 days) after BLM injection. Blood and lungs were processed for
biochemical and morphological analysis as described in the following
sections.
2.2.2. Lung histology and immunohistochemistry for α-SMA
After death, lung tissues were fixed by inflation with a buffered 10%
formalin solution for 24 h and then embedded in paraffin. Tissues were
then sectioned, stained with Mallory trichrome for collagen staining and
examined for pulmonary fibrosis.
Some of the lung sections (3–4 μm) were used for immunohisto-
chemistry. The expression of α-SMA marker was performed on lung sec-
tions by using “α-SMA ImmunoHistology Kit” (IMM-2, Sigma), following
manufacturer's instructions.
2.2.3. Collagen measurement
Collagen content was determined by hydrolyzing lung samples in
6 N HCl and by measuring hydroxyproline according to the method
of Kivirikko [48]. Collagen content was estimated by multiplying the
amount of hydroxyproline by a factor of 7.69. Results are expressed as
milligram of collagen per gram of lung (wet weight).
2.2.4. F⁠2-IsoPs in lungs and plasma
For plasma free F⁠2-IsoP determination, platelet poor plasma was ob-
tained from heparinized blood by centrifugation at 2400×g and buty-
lated hydroxytoluene (BHT) (final concentration 90 μM) was added to
plasma as an antioxidant. Aliquots of plasma were stored under nitro-
gen at −70 °C until analysis (within 2 months). Immediately after thaw-
ing, sample acidification (2 ml of acidified water, pH 3) was carried out
and plasma (1 ml) was spiked with tetradeuterated prostaglandin PGF⁠2α
(PGF⁠2α-d4) (500 pg in 50 ml of ethanol) as an internal standard. Plasma
sample extraction and purification were performed by solid–phase sep-
aration steps: an octadecylsilane (C18) cartridge followed by an amino-
propyl (NH⁠2) cartridge [49,50].
For lung total (sum of free and esterified) F⁠2-IsoP determination, tis-
sue was frozen in dry ice and stored at −80 °C until assay. At the time of
the assays, sample was homogenized (10% w/v) in phosphate-buffered
saline, pH 7.4. Aqueous KOH (1 mM, 500 μl) was added to an aliquot
(1 ml) of lung homogenate. After incubation at 45 °C for 45 min, pH
was adjusted to 3 by adding HCl (1 mM, 500 μl). Each sample was
spiked with PGF⁠2α-d⁠4 (500 pg), as an internal standard, and ethyl acetate
(10 ml) was added to extract total lipids by vortex-mixing and centrifu-
gation at 1000g for 5 min at room temperature. The total lipid extract
was applied to an NH⁠2 cartridge and isoprostanes were eluted [50,51].
For both plasma and lung eluted samples, the carboxylic group
was derivatized as the pentafluorobenzyl ester whereas the hydroxyl
groups were converted to trimethylsilyl ethers. F⁠2-IsoP determinations
were carried out by gas chromatography/negative ion chemical ioniza-
tion tandem mass spectrometry (GC/NICI-MS/MS) analysis. The mea-
sured ions were m/z 299 and m/z 303 derived from the [M-181]⁠- pre-
cursor ions (m/z 569 and m/z 573) produced from the derivatized
15-F⁠2t-IsoP (the most represented isomer for F⁠2-IsoP measurement) and
the PGF⁠2α-d⁠4, respectively [49].
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2.3. In vitro study
2.3.1. Rat lung fibroblast (RLF) isolation
Cells were isolated as previously described [52] and modified by
our group [53]. Cells were maintained in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal bovine serum (FBS)
and antibiotics and then seeded at 10⁠6 cells/flask (25 cm⁠2). An aliquot
of freshly isolated RLF were seeded on coverslips in 24-well plates to
evaluate the expression of α-SMA. The remaining cells were incubated
at 37 °C in 95% air-5% CO⁠2. Upon reaching confluence, cells were
trypsinized, counted, seeded in flasks and used for the following experi-
ments.
2.3.2. Treatment with bleomycin or F⁠2-IsoPs
Cells were seeded at a density of 6 × 10⁠4 cells/ml in DMEM supple-
mented with 10% FBS and allowed to grow to confluence. Twenty-four
hours before the treatment, the medium was changed to serum-free
DMEM. Cells were then treated with either BLM (0.1–100 mU/ml) or
with 15-F⁠2t-IsoP (Cayman Chemical, USA) in the range of concentrations
(10⁠–14–10⁠–12 M). A stock solution of 15-F⁠2t-IsoP (1 mg/ml in ethanol)
was diluted to a concentration of 10⁠−5 M and then further diluted to fi-
nal concentrations with DMEM.
2.3.3. Determination of total F⁠2-IsoPs in RLF
RLF were seeded in T75 flasks (6 × 10⁠6 cells/flask) and treated with
BLM (50 mU/ml) for 24 h. Cells were then harvested and the pellet
was suspended again with 90 μM of the antioxidant BHT. Subsequently,
samples were sonicated for 30 s and then incubated at 45 °C for 45 min
in presence of 0.5 N KOH for the basic hydrolysis. The samples were
then acidified to pH 3 with HCl (final concentration 0.5 N), and spiked
with PGF⁠2α-d⁠4 (500 pg) as internal standard. After extraction with ethyl
acetate, the total lipids were applied to a NH⁠2-cartridge. The final
eluates were derivatized to pentafluorobenzyl ester and trimethylsilyl
ethers. As for plasma and lung samples, identification and quantifica-
tion of the ions m/z 299 and m/z 303 (derived from 15-F⁠2t-IsoP and
PGF⁠2α-d⁠4, respectively) were performed by GC/NICI-MS/MS [54]. Total
F⁠2-IsoPs levels were expressed as pg/10⁠6 cells.
2.3.4. DNA synthesis
For the evaluation of cell proliferation, ⁠3H-thymidine incorporation
was measured, according to Boscoboinik et al. [55] in 24-well plates.
Sub-confluent cells were incubated with either BLM or 15-F⁠2t-IsoP for
24 h in serum-free DMEM. Six hours before the measurements, 10 μCi/
ml of ⁠3H-thymidine were added. Cell layers were then washed, fixed for
20 min with ice-cold 5% trichloroacetic acid (TCA), and solubilized in
0.4 ml of 0.1 M NaOH/ 2% Na⁠2CO⁠3. Samples were mixed with 8 ml of
Ultima Gold (Packard) and counted for radioactivity in a Packard 2100
TriCarb activity liquid scintillation analyzer. Results are expressed as
⁠3H-thymidine incorporation (dpm) per well.
2.3.5. Collagen synthesis
To evaluate the effect of BLM or F⁠2-IsoPs on collagen metabolism,
RLF were seeded on 12-well plates and grown to visual confluence.
Medium was changed to serum-free DMEM for 24 h to allow the cells
to become relatively quiescent. In addition to DMEM, 11.5 μg/ml L-pro-
line, 50 μg/ml ascorbic acid, 50 μg/ml β-aminopropionitrile were
added. After incubation, cells were treated either with BLM or
15-F⁠2t-IsoP (which is currently used as biomarker of in vivo F⁠2-IsoP for-
mation) for 48 h. Collagen synthesis was assessed as previously reported
[46]. Briefly, 16 h before the end of the 48 h treatment, 10 μCi/ml of
⁠3H-proline (Amersham International; specific activity 23 Ci/mmol) were
added to each well. Media was harvested for determination of ⁠3H-pro-
line incorporation into collagen and non-collagen proteins following the
collagenase digestion method, by using highly purified bacterial colla-
genase (Calbiochem Cat. no. 234134, 250 IU). Incorporation of radioac-
tivity into collagen and non-collagen proteins was determined following
precipitation with TCA. Collagen-incorporated radioactivity was recov-
ered in the TCA-soluble fraction, while non-collagen radioactivity was
recovered from TCA precipitate. Percentage collagen synthesis was esti-
mated as previously reported [56].
2.3.6. Expression of α-SMA in rat lung fibroblasts
Freshly isolated cells were grown on coverslips and α-SMA expres-
sion was evaluated by “α-SMA ImmunoHistology Kit” (IMM-2, Sigma)
at III, V and VIII day, after treatment with 15-F⁠2t-IsoP. Cells were
fixed with cold acetone at 4 °C for 5 min to block endogenous perox-
idases, washed twice with PBS and incubated with 0.5% BSA in PBS
for 30 min. Cells were incubated with the primary monoclonal antibody
raised against α-SMA for 1 h and then with the appropriate biotinylated
secondary antibody for 20 min. At the end of incubation, Peroxidase
reagent was added for 20 min. Following PBS washes, cells were incu-
bated with Substrate Reagent for 5 min, washed with water and coun-
terstaining with 0.2% Fast-Green in water for 8 min. At last, coverslips
were washed with water, fixed on glass and observed on microscope.
2.4. Identification of TP receptor on RLF
2.4.1. Immunoblot analysis for TP receptor
Western Blots were performed in both freshly isolated and activated
RLF. An aliquot of freshly isolated cells was resuspended in the lysis
buffer (50 mM Tris-HCl, 10 mM EDTA, 10 mM EGTA, 10 mM iodoac-
etammide, 0.02% sodium azide and 0.01% PMSF) and placed on ice for
30 min. Cells were homogenized, sonicated and centrifuged for 45 min
at 40,000g at 4 °C. In parallel, activated RLF were seeded and al-
lowed to reach confluence. Cells were then collected from the culture
plates, resuspended in the lysis buffer and treated as described above for
freshly isolated cells. Pellets from both cell preparations were collected
and resuspended in the lysis buffer. An aliquot of membrane protein
(30 μg) was loaded in each lane, separated electrophoretically in 10%
SDS-PAGE and transferred onto a nitrocellulose membrane. Immunoblot
was performed using a polyclonal antibody raised against human TP re-
ceptor (1:1000) (Cayman Chemical, Ann Arbor, USA). Secondary goat
anti-rabbit IgG antibody (BioRad, Hercules, CA, USA) (1:15000) was
added to the membrane. Immunodetected proteins were visualized us-
ing ECL assay kit (Amersham Biosciences), following the manufacturer's
recommended protocol.
2.4.2. Binding studies
Cells were seeded on 12-well cell plates as 6 × 10⁠4 cells/ml and used
when they reached confluence. After washing twice with PBS, cells were
incubated with a specific TxA⁠2r antagonist, ⁠3H-SQ29548 (Perkin Elmer,
Boston, MA, USA; specific activity 48.2 Ci/mmol), in the concentration
range of 1.25–20 nM for 2.5 h at 4 °C, as previously described [36].
The reaction was terminated by four washes with ice-cold PBS to re-
move unbound ligand. Cells were dissolved in 1 ml 1 N NaOH followed
by neutralization with 1 ml 1 N HCl. Radioactivity was counted in a
Packard 2100 TriCarb liquid scintillation analyzer. Specific binding was
calculated as the difference between binding measured in the absence
and presence of unlabeled SQ29548 (10 μM). The maximum number of
binding sites (Bmax) and the dissociation constant (Kd) were calculated
by nonlinear regression analysis of the saturation curve performed by
one-site curve fit.
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2.4.3. Colocalization of α-SMA and TP receptor on lung fibroblasts
Fibroblasts were grown on coverslips and fixed with cold acetone
at 4 °C for 5 min. The colocalization of α-SMA and TP receptor on RLF
was performed by a first block of nonspecific binding with 3% BSA in
PBS for 1 h, followed by incubation with primary monoclonal mouse
antibody anti-α-SMA (Sigma) (1:100) for 1 h. After washing with PBS,
cells were incubated for 1 h with TRITC-conjugated anti-mouse IgG
(Sigma, St Louis, MO, USA) (1:200). A second block for nonspecific im-
mune-binding sites was performed with 3% BSA, and cells were incu-
bated for 1 h with rabbit polyclonal antibody raised against human TP
receptor (1:100 in 0.3% BSA/PBS). After 1 h incubation with FITC-con-
jugated anti-rabbit IgG (Sigma, St Louis, MO, USA) (1:200), the im-
munofluorescence was analyzed by a Nikon Eclipse TE300 microscope.
2.5. Inhibition experiments
To investigate whether the fibrogenic effects of F⁠2-IsoP in RLF are
mediated by TP binding, experiments on DNA and collagen synthesis
were carried out in the presence of SQ29548 (Cayman Chemical, Ann
Arbor, USA), a specific TP antagonist. Subconfluent cells were made
quiescent by incubation in serum-free DMEM and then treated with
15-F⁠2t-IsoP (10⁠−13 M) in the presence or absence of SQ29548, in a
1:10 M ratio. DNA and collagen synthesis were estimated as reported
under previous paragraphs (Sections 2.3.4. and 2.3.5.).
2.6. Statistical analyses
The results of each experimental in vitro condition were determined
from the mean of triplicate experiments. For the in vivo studies, 6 ani-
mals per group were used unless noted otherwise. An independent sam-
ple two-tailed Student's t-test was used to assess the significance be-
tween the two groups. Statistical analysis was carried out by analysis of
variance followed by appropriate post hoc tests including multiple com-
parison tests. Nonlinear regression analysis and statistical analysis were
performed using commercially available software (Prism 4.0; GraphPad
Software Inc., San Diego, CA, USA). All data are expressed as means ±
standard deviation (SD). The value of P < 0.05 was considered statisti-
cally significant.
3. Results
3.1. In vivo study
3.1.1. BLM-induced lung fibrosis
Administration of BLM was associated with an increase in collagen,
in particular in perialveolar areas. By day 7, tissues showed progressive
morphological changes and a regional interstitial fibrosis which became
more pronounced at 28 days (Fig. 1). Control lungs from animals in-
stilled with saline did not demonstrate any pathologic changes at any of
the time points.
In contrast to earlier time points (and control lungs), after 21 days,
lung sections showed α-SMA positive cells, of which the majority were
evident at day 28 (Fig. 2). The expression of α-SMA demonstrates the
population of cells being composed of myofibroblasts (fibroblastic foci).
This feature was absent at 7 days and in controls.
Similarly, biochemical evaluation of hydroxyproline showed a pro-
gressive increase in lung collagen content in BLM-treated rats (10.25
± 0.41–34.24 ± 0.62 mg/g tissue) when compared to saline treated
rats (7.34 ± 0.35–16.27 ± 0.65 mg/g) (Fig. 3A). In comparison to
saline treated rats, the BLM treatment also induced significant progres-
sive increases in total lung F⁠2-IsoPs (Fig. 3B).
Along the experimental time (0–28 days), a significant positive cor-
relation between lung collagen content and the amount of F⁠2-IsoPs in
the lung was observed (r = 0.9274, P < 0.001).
As depicted in Fig. 3C, plasma F⁠2-IsoP levels showed a significant
increase compared to controls, with a peak at 7 days after treatment
(+107%) and remained elevated for the entire experimental period
(about 60%).
3.2. In vitro study
3.2.1. Effect of BLM on lung fibroblasts
RLF incubated with different BLM concentrations (0.1–100 μg/ml)
showed increased levels of cell proliferation (Fig. 4A) and collagen syn-
thesis (Fig. 4B). In particular, treatment with 50 μg/ml of BLM induced
the highest response in cell proliferation and collagen synthesis. Al-
though, both parameters decreased at 100 μg/ml of BLM concentration,
they remained higher than the controls.
Fig. 1. Effect of bleomycin (BLM) on lung histological changes. Rats were treated with a single intratracheal instillation of saline or BLM and the lungs were harvested for Trichrome
staining at different time points after treatment, as described in the Section 2. Shown is representative histology from rats in BLM-treated group. Histological signs of fibrosis are evident
since day 7 and progressively increase until 28 days. Original magnification, 100×.
Fig. 2. Immunohistochemical analysis of lung sections from rats treated with BLM. Cells positive to α-SMA are evident after 21 and 28 days of treatment with BLM, while are absent
at 7 days. Original magnification, 200×.
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Fig. 3. Lung collagen content and F⁠2-IsoP levels in rats after chronic intoxication
with BLM. Rats were treated with BLM and the parameters were evaluated after 7, 14,
21 and 28 days. (A) Lung collagen content was assayed as reported in Section 2 and cal-
culated by multiplying the hydroxyproline content for the conversion factor, 7.69. Results
are expressed in mg of collagen/g rat lung. F⁠2-IsoP levels in lung (B) and plasma (C) are
reported as pg/mg of tissue protein and pg/ml plasma, respectively. Data are expressed as
means ± SD from 3 controls and 5 BLM-treated animals. *P < 0.05, **P < 0.01, ***P <
0.001 vs. respective control.
Moreover, the same concentration of BLM (50 μg/ml) induced a
3-fold increase in the levels of F⁠2-IsoPs released in culture media (Fig.
5).
3.2.2. Effect of 15-F⁠2t-IsoP on fibroblast proliferation and collagen
synthesis
To investigate whether F⁠2-IsoPs have a biological effect on RLF, we
studied the effect of 15-F⁠2t-IsoP (the most representative F⁠2-IsoP iso-
mer) on two main hallmarks of fibrosis. The addition of 15-F⁠2t-IsoP
(10⁠–12–10⁠–14 M) to cultured activated pulmonary fibroblasts induced an
increase in both DNA (+74%) and collagen synthesis (+35%) (Fig. 6A
and B). The most active concentration for both parameters was 10⁠–13 M.
3.2.3. Effect of F⁠2-IsoPs on lung fibroblast activation
To determine whether F⁠2-IsoPs play a role in RLF activation, α-SMA
expression was evaluated. After 3 days of culture, there was no evidence
of α-SMA expression in control or treated cells. However, after five days
of treatment with 15-F⁠2t-IsoP, α-SMA expression was more evident in
RLF compared to control. After 8 days of treatment, the expression of
α-SMA in treated cells had increased approximately 2-fold compared to
control cells. These results demonstrate that F⁠2-IsoPs can more readily
activate cultured RLF to myofibroblasts (Fig. 7).
3.3. Identification and localization of TP receptor in lung fibroblasts
3.3.1. Immunoblot and binding studies
Immunoblot analysis of membrane proteins from activated RLF re-
vealed the presence of a single immunoreactive band of 55 kD corre-
sponding to TP receptor (Fig. 8, lane B). Molecular weight of this band
corresponds to a TP receptor previously found in activated HSC [36].
No band was detected in freshly isolated RLF (Fig. 8, lane A).
Binding studies were carried out to characterize the population of TP
receptors on lung fibroblasts. Analysis of the saturation curve by non-
linear regression indicated that ⁠3H-SQ29548 binds to a single class of
receptors on RLF, with a dissociation constant (Kd) of 1.22 ± 0.11 nM
and a maximal binding capacity (Bmax) of 5.28 ± 0.01 fmol/well (Fig.
9).
This result is very similar to that presented in our previous work on
activated HSC (Kd = 1.42 ± 0.33 nM; Bmax = 5.91 ± 0.36 fmol/well)
[36].
3.3.2. Colocalization studies
Colocalization studies carried out with immunofluorescence con-
firmed the presence of TP receptor on activated lung fibroblasts. In fact,
3 days after cell isolation, both control and F⁠2-IsoPs-treated fibroblasts
were negative for the analyzed markers. From the fifth day onward, the
TP receptor (evidenced in green) is present in both control and treated
fibroblasts (Fig. 10). However, cells treated with F⁠2-IsoPs displayed a
higher expression of TP compared to the matched controls. Cells ex-
pressing only α-SMA appeared red (red arrow), while when α-SMA colo-
calizes with TP the cells appeared yellow-orange (merge, white arrow).
Fig. 10 shows that the presence of TP is paralleled by the expression of
α-SMA, which is more evident in RLF treated with F⁠2-IsoPs. At day 8, all
fibroblasts showed co-expression of both markers (yellow-orange) (Fig.
10).
3.3.3. Inhibition experiments
Inhibition experiments were carried out to evaluate whether the fi-
brogenic effects induced by F⁠2-IsoPs in RLF are elicited through the
binding to TP receptor. Cells were incubated in the presence of both
15-F⁠2t-IsoP and the specific TP antagonist SQ29548, in a molar ratio
of 1:10, and DNA and collagen synthesis were measured. As shown in
Fig. 11 (A and B), the stimulatory effect of F⁠2-IsoPs on both parameters
were inhibited by SQ29548 co-incubation. These results are in agree-
ment with our binding studies demonstrating that RLF express a popula-
tion of receptors that specifically bind to the TP antagonist ⁠3H-SQ29548.
This further strengthens our hypothesis of TP receptor involvement in
F⁠2-IsoPs-evoked responses in RLF.
4. Discussion
Although the precise mechanisms of pulmonary fibrosis are not fully
understood, disruption of the oxidant/antioxidant balance in the lung
is thought to play an important role in many of the processes lead-
ing to inflammation and fibrosis [57,58]. F⁠2-IsoPs belongs to a class of
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Fig. 4. Effect of BLM on RLF proliferation (A) and collagen synthesis (B). RLF were isolated and treated with BLM at different concentrations. (A) Cell proliferation was evaluated
after 24 h by measuring ⁠3H-thymidine incorporation in RLF. Results are expressed as percentage of untreated controls. (B) Collagen content was evaluated after 48 h by measuring the
ratio of ⁠3H-proline incorporation into collagen and non-collagen proteins. Results (collagen/total protein) are presented as percentage of untreated controls. Data are means ± SD of 3
experiments. *P < 0.05 vs. Control, **P < 0.01 vs. Control.
Fig. 5. Effect of BLM on F⁠2-IsoP release in RLF. To assess the effect of BLM in RLF,
F⁠2-IsoP levels were evaluated after 24 h of treatment with 50 µg/ml of BLM. Compared
to controls, BLM-treated RLF showed increased levels of F⁠2-IsoPs. Data are expressed as
means ± SD of 3 experiments. **P < 0.01 vs. Control.
metabolites produced during OS in different pathologies, including pul-
monary diseases.
Elevated levels of F⁠2-IsoPs were found in EBC of patients with cystic
or interstitial pulmonary fibrosis [27,59], as well as in serum and bron-
choalveolar lavage in IPF [29].
The experimental induction of pulmonary fibrosis by means of BLM
is a well-described model in which OS is known to contribute to pathol-
ogy [5,60,61]. The role of ROS in the pathogenesis of BLM-induced
lung injury is largely known, and the absence of ROS production results
in protection of the animals against BLM-induced pulmonary fibrosis
[60,62–64]. Furthermore, BLM is known to cause an increase in 4-hy-
droxy-2,3-nonenal (HNE), one of the major bioactive markers of lipid
peroxidation [65,66]. HNE is able to induce TGFβ1 expression, which is
crucial for the pathogenesis of this disease [67].
However, little information is available on the role of F⁠2-IsoPs in
pulmonary fibrosis. Only few studies carried out in animal models of
BLM-induced lung fibrosis reported a local increase of F⁠2-IsoPs in lung
tissue [58,68,69], and these observations were limited to 3–8 days after
BLM treatment.
In the present work, we demonstrated that lung F⁠2-IsoP values pro-
gressively increased up to 28 days in animals receiving BLM, and pos-
itively correlated with lung collagen content. We also showed that
F⁠2-IsoPs rapidly increased in plasma following administration of BLM,
reaching values 2 times those of controls by day 7. This increase was
associated with the development of fibrosis, as evaluated histologically
and biochemically. Our results suggest that plasma levels of IsoPs may
be considered as an indicator of oxidant-induced lung damage during
BLM-induced pulmonary fibrosis.
Although F⁠2-IsoPs are widely recognized to evoke a variety of bi-
ological responses in airway and pulmonary vascular smooth muscle
cells [31,32], their effect on lung fibroblasts and pulmonary fibrosis is
largely unstudied. Fibroblasts are the most common connective tissue
cells. Under precise stimulatory signals, fibroblasts either transform to
myofibroblasts or proliferate, resulting in vascular occlusion or areas of
fibroblastic foci. Fibroblastic foci are thought to be the sites of active
collagen and elastic synthesis with excessive deposition of extracellular
matrix components [70–72].
In previous studies, we demonstrated that BLM increased cell prolif-
eration and collagen synthesis in cultured human lung fibroblasts [46].
In our present work, similar data was obtained on RLF. Of interest,
when these cells were treated with BLM, a marked release of F⁠2-IsoPs
in the medium was observed. This demonstrated that fibroblasts may
be a source of F⁠2-IsoPs in OS-induced lung injury. With the aim to clar-
ify the possible role of F⁠2-IsoPs as mediators of fibrotic events, RLF
were directly treated with 15-F⁠2t-IsoP. This resulted in a significant in
Fig. 6. Effect of 15-F⁠2t-IsoP on proliferation (A) and collagen synthesis (B) in RLF. Cells were treated with increasing concentrations of 15-F⁠2t-IsoP as described in Section 2. (A) DNA
synthesis was evaluated as ⁠3H-thymidine incorporation. (B) Collagen synthesis was evaluated as a ratio of ⁠3H-proline incorporation into collagen and non-collagen proteins. Results are
presented as percentage of untreated controls. Data are expressed as means ± SD of 3 experiments. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Control.
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Fig. 7. Effect of F⁠2-IsoPs on freshly isolated RLF. Cells were isolated and treated with 10⁠−13 M 15-F2t-IsoP as described in Section 2. Fibroblast activation was examined immunocyto-
chemically by evaluating α-SMA expression at 3, 5 and 8 days of culture. Original magnification, 100×.
Fig. 8. Western blotting of TP receptor in RLF. Proteins were extracted from membrane
lysates of both freshly isolated and activated cells. Immunoblot analysis was performed
with a polyclonal antibody raised against TP receptor (1:1000). The figure shows a mem-
brane protein of 55 kDa corresponding to TP in activated RLF (lane B). No band was de-
tected in freshly isolated cells (lane A). Blots were reprobed with β-actin to assess equal
loading.
Fig. 9. Scatchard plotting of ⁠3H-SQ29548 binding on RLF. Cells were incubated with
⁠3H-SQ29548 (1.25–20 nM). Specific binding was calculated as the difference between
binding measured in the absence and presence of unlabeled 10 mM SQ29548. Each point
was run in quadruplicate. Data are the means ± SD of three experiments.
crease of cell proliferation and collagen synthesis, further confirming
our previous data obtained in hepatic stellate cells [35,73,74].
A large body of literature has demonstrated that pulmonary fibro-
sis is often characterized by an increase in the number and volume of
cells expressing α-SMA and procollagen mRNA, referred as myofibrob-
lasts [75,76]. These cells have been found in IPF and in experimental
BLM-induced lung fibrosis and are considered to be the main source
of collagen hyperproduction. However, the stimulus and the underlying
processes by which fibroblasts differentiate into myofibroblasts are still
debated.
We found these fibroblastic foci in lung sections of rats treated with
BLM and demonstrated in vitro that F⁠2-IsoPs are able to activate fibrob
lasts to myofibroblasts (as evaluated by α-SMA expression). Our results
indicate that F⁠2-IsoPs may be involved both in the activation of fibrob-
lasts and in the stimulation of cell proliferation and collagen synthesis,
both key events in the fibrotic process.
Although the mechanism through which F⁠2-IsoPs stimulate fibrob-
lasts is unknown, some studies demonstrated that in different cell types
they act through receptors analogous to those for thromboxane A2
(TxA⁠2) (TP receptors) [36,77,78] We previously reported that HSC ex-
press high-affinity receptors for TxA⁠2 ligands on their surface, and that
fibrogenic effects in the liver were elicited by F⁠2-IsoPs through these re-
ceptors, which set the MAPK and IP3 pathways into motion [36,37,73].
In this work, we showed that TP receptor is also present on RLF
and colocalizes with α-SMA. To our knowledge, this is the first study
demonstrating the presence of the TP receptor on RLF. Binding studies
demonstrated that RLF present a single class of receptors that specifi-
cally bind to the TxA⁠2r antagonist ⁠3H-SQ29548, showing an affinity of
ligand binding (Kd) and a density of receptors (Bmax) very similar to
those previously found in HSC [36]. Finally, our inhibition studies indi-
cated that the fibrogenic response induced by F⁠2-IsoPs in RLF is elicited
through the binding to TP receptor. Our present results, combined with
those previously obtained in HSC [37], contributed to the hypothesis
that F⁠2-IsoPs trigger a shared fibrogenetic mechanism in fibroblasts and
fibroblast-like cells.
Further studies are needed to elucidate which pathways are acti-
vated by these compounds in lung fibrosis.
5. Conclusion
This study indicates that F⁠2-IsoPs are in vivo markers of OS during
pulmonary fibrosis and also serve as key regulators of fibrogenesis by
activating fibroblasts to myofibroblasts and by inducing cell prolifera-
tion and collagen synthesis. These effects are mediated by the TP recep-
tor which we found to be expressed by RLF. Together, our results may
have important implications in the development of more effective ther-
apies for lung fibrosis.
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Fig. 10. Colocalization of TP receptor and α-SMA in RLF. Activated cells expressed both TP receptor (green labelled) and α-SMA (red labelled). Merged images (yellow-orange) show
the degree of colocalization of both markers. Nuclei were stained with DAPI reagent. Original magnification, 400×. (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article).
Fig. 11. Effect of 15-F⁠2t-IsoP and SQ on proliferation (A) and collagen synthesis (B) in RLF. Cells were treated with 15-F⁠2t-IsoP (10⁠−13 M) and the specific TP antagonist SQ29548, in
a molar ratio of 1:10, as described in Section 2. (A) DNA synthesis was evaluated as ⁠3H-thymidine incorporation. (B) Collagen synthesis was evaluated as a ratio of ⁠3H-proline incorporation
into collagen and non-collagen proteins. Results are presented as percentage of untreated controls. Data are expressed as means ± SD of 3 experiments. *P < 0.05 vs. Control; #P < 0.05
vs ISO; ###P < 0.001 vs ISO; C, Control; SQ, SQ29548; ISO, 15-F⁠2t-IsoP.
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